



Investor Newsletter

Symbol: ZYXI

June 2012

Zynex Ranked 2nd Fastest Growing Colorado Public Company

LONE TREE, Colo. – October 18, 2011 -

Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced that the Denver Business Journal ranked Zynex 2nd fastest growing public company in Colorado, as measured by percentage of net income growth from 2008 to 2010.

Thomas Sandgaard, Zynex's CEO commented, "We are pleased to be recognized and especially grateful to make the top of this list, as it highlights the dedication of our employees and continued growth of our company. We believe we will continue our success in the coming months and years."

Zynex Inc. revenues for 2010 were \$24.1 million; \$18.6 million in 2009; \$11.7 million in 2008; and \$8 million in 2007. The company has remained profitable throughout the 4 years, despite the recent recession.

Zynex Ranked 9th in Revenue Growth Among Medical Equipment Companies

LONE TREE, Colo. – October 24, 2011 -

Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced that it has been ranked 127th on Deloitte's 2011 Technology Fast 500 list for revenue growth between 2006 and 2010. The same list categorizes companies into various industries and Zynex was ranked 9th in growth among all medical equipment companies in the US and Canada. The list also indicates that Zynex is the fastest growing medical equipment company in the Rocky Mountain region (for two years in a row), as well as 2nd fastest growing company in Colorado among all technology companies. The Deloitte Technology Fast 500 list can be found at fast500.com. Zynex's revenue grew 842% from the period of 2006 to 2010, with revenue in 2010 of \$24,085,000.

About The Deloitte Technology Fast 500™

Each year companies innovate, overcome obstacles and systematically defy the odds. The Technology Fast 500 program recognizes these efforts in its annual ranking of the 500 fastest-growing technology companies in the United States and Canada. The program is based on percentage revenue growth from 2006 to 2010 and recognizes all areas of technology and includes both public and private companies.

Zynex First Quarter 2012 Revenue Grows 35%

LONE TREE, Colo. – May 8, 2012 -

Zynex, Inc. (OTCBB: ZYXI), total net revenue increased 35% to \$8,944,000 for the 3 months ended March 31, 2012 from \$6,633,000 for the 3 months ended March 31, 2011. The Company generated net income of \$320,000, or \$0.01 per share in the first quarter of 2012, versus a net loss of \$110,000, or less than \$0.01 per share in the first quarter of 2011.

The Company reported a gross profit of \$7,131,000, or 80% of net revenue, for the first three months of 2012, as compared to a gross profit of \$5,189,000, or 78% of net revenue, for the first three months of 2011.

The Company reported Selling, General and Administrative (SG&A) expenses of \$6,645,000, or 74% of net revenue, for the three months ended March 31, 2012, as compared to \$5,328,000, or 80% of net revenue, for the three months ended March 31, 2011.

The Company generated a first quarter 2012 income from operations of \$486,000, income before income taxes of \$393,000 and net income of \$320,000, or \$0.01 per share, versus a first quarter of 2011 loss from operations of \$139,000, loss before income taxes of \$197,000 and net loss of \$110,000, or less than \$0.01 per share.

Zynex 2011 Financial Results

LONE TREE, Colo. - March 15, 2012 -

Zynex, Inc. (OTCBB: ZYXI), Zynex net revenue increased 42% to \$34,148,000 for 2011 from \$24,085,000 for 2010. The Company generated 2011 net income of \$1,564,000, or \$.05 per share, versus 2010 net income of \$350,000 or \$.01 per share, representing a five-fold increase year over year.

The Company reported a gross profit of \$26,777,000, or 78% of net revenue, for 2011, as compared to a gross profit of \$18,883,000, or 78% of net revenue, for 2010.


The Company reported Selling, General and Administrative (SG&A) expenses of \$23,676,000, or 69% of net revenue, for 2011, as compared to \$17,322,000, or 72% of net revenue, for 2010.

The Company generated 2011 income from operations of \$3,101,000, income before income taxes of \$2,644,000 and net income of \$1,564,000, versus 2010 income from operations of \$1,561,000, income before income taxes of \$1,335,000 and net income of \$350,000.

Outlook:

The Company anticipates net revenues of between \$38 million and \$40 million for 2012 and net income per diluted share of between \$0.06 and \$0.08 for 2012.

Revenue Trend



Zynex Closes \$7.0 Million Line of Credit

Doral Healthcare Finance (DHF) provided a three year \$7.0 million revolving line of credit to Zynex, Inc., and subsidiaries ("Zynex"). Proceeds from the transaction were used to pay off existing debt and for growth. "DHF successfully structured a working capital line that addressed the two restrictions that were in place with Zynex's current lender; a line large enough to support Zynex's operating cash flow needs and the flexibility in the line to accommodate potential acquisitions," said Jennifer Sheasgreen, DHF Managing Director. Thomas Sandgaard, President and CEO of Zynex, commented, "This new line of credit provides us substantial flexibility to execute our strategic business plan. We are excited to work with DHF, as they understand our business model and believe they will be a great partner for our future."

The information presented is from the company's press release and SEC filings as of the dates referenced:

www.zynex.com
www.sec.gov



June 2012

Investor Newsletter

Symbol: ZYXI

Zynex News

Zynex Acquires NeuroDyne Medical, Corp. *March 12, 2012*

Zynex acquired substantially all of NeuroDyne's assets for the sum of \$403,000 (\$245,000 in cash and \$158,000 in Zynex restricted common stock). The transaction included a seven year earn-out incentive, based on a percentage of net revenue generated by NeuroDyne products. NeuroDyne's CEO was appointed as VP of Technical Support for the Zynex NeuroDiagnostics subsidiary. NeuroDyne Medical, Corp., located in Cambridge, Massachusetts, is an 18 year old manufacturer of advanced medical devices for non-invasive measurement of sEMG and autonomic nervous systems. The devices can be used for evaluation and treatment of neurological and neuromuscular disorders as well as education and research. NeuroDyne's products include medical instruments, sensors, disposable electrodes and software that offer sEMG, EKG, EEG, respiration, skin temp, EDR, EDL, peripheral blood flow, IBI, heart rate, and heart rate variability. The products are sold and used by healthcare providers, educators and researchers. NeuroDyne's customers include some of the top health services providers in the country. Thomas Sandgaard, CEO of Zynex, commented, "This acquisition is important for us as it adds established product lines and sales channels that we expect will fuel growth in our NeuroDiagnostics division. Our long-term goal is to generate sales and profits in our NeuroDiagnostics division that will match our electrotherapy division, Zynex Medical. Products in Zynex NeuroDiagnostics are sold domestically to clinics and hospitals as capital goods, and internationally through distributors."

Zynex Expands Internationally – Forms European Subsidiary *February 9, 2012*

Zynex, Inc. announced the creation of a European, wholly owned subsidiary in Denmark, which will initially focus on sales and marketing within the European marketplace. Thomas Sandgaard, CEO of Zynex stated, "We believe that considerable revenue opportunities exist in the global medical device marketplace. Establishing a subsidiary in Europe is the next phase in our international expansion strategy."

Zynex Receives FDA 510(k) Clearance for the NexWave Medical Device *Sept. 26, 2011*

The NexWave device is the next generation in electrotherapy treatment and will be manufactured, marketed and sold through our Zynex Medical subsidiary. This device is capable of delivering three modalities of stimulation; traditional TENS, interferential and neuromuscular electrical stimulation. The combined modalities of the NexWave provide a wide variety of pain and muscle rehabilitation therapies through one device. Zynex's CEO, Thomas Sandgaard, commented; "We are very excited about the market introduction of this new product. The combined modalities of our NexWave provide doctors and clinicians a more comprehensive pain therapy solution for their patients. This device was designed with the patient in mind, as it is compact and easy to use, and falls under existing medical billing codes. We believe this new product is unique in the electrotherapy industry and will provide our expanding sales force an additional tool to fuel revenue generation in our already rapid growing Zynex Medical subsidiary."

Thomas Sandgaard, CEO named a finalist in the Ernst & Young Entrepreneur Of The Year® *June 11, 2012*

2012 program in the Mountain Desert region which includes Colorado, Arizona and New Mexico. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Now in its 26th year, the Entrepreneur Of The Year Program has expanded to recognize business leaders in more than 140 cities in more than 50 countries throughout the world.

Annual Financial Data	2011	2010	2009	2008	2007	2006
Net Revenue	\$34,148	\$24,085	\$18,681	\$11,764	\$8,048	\$2,557
Gross Profit	26,777	18,883	14,888	9,524	7,319	2,253
Net Income (loss)	1,564	350	2,382	111	2,131	(320)
Cash	789	602	863	--	--	265
EPS	0.05	0.01	0.08	0.00	0.07	(0.01)
Cash Flow from Operations	(362)	(665)	3,648	(715)	746	(483)
Total Stockholders Equity	10,140	8,182	7,486	4,774	3,618	1,287
Common Shares Outstanding	30,800	30,600	30,500	29,900	26,800	26,300

Amounts in Thousands except per share data.

About Zynex

Zynex (founded in 1996), operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex Medical's product lines are fully developed, FDA-cleared and commercially sold worldwide. Zynex NeuroDiagnostics, sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.

For additional information, please visit: <http://www.ir-site.com/zynex/default.asp>.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2011.

Contact: Zynex, Inc. Anthony Scalese, CFO, 303-703-4906



June 2012

Investor Newsletter

Symbol: ZYXI



Symbol: ZYXI